These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20719246)

  • 21. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
    Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
    Quintilio W; Kubrusly FS; Iourtov D; Miyaki C; Sakauchi MA; Lúcio F; Dias Sde C; Takata CS; Miyaji EN; Higashi HG; Leite LC; Raw I
    Vaccine; 2009 Jun; 27(31):4219-24. PubMed ID: 19393709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.
    van Roosmalen ML; Kanninga R; El Khattabi M; Neef J; Audouy S; Bosma T; Kuipers A; Post E; Steen A; Kok J; Buist G; Kuipers OP; Robillard G; Leenhouts K
    Methods; 2006 Feb; 38(2):144-9. PubMed ID: 16414272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response.
    Szyszko E; Brokstad K; Cox RJ; Hovden AO; Madhun A; Haaheim LR
    Scand J Immunol; 2006 Nov; 64(5):467-75. PubMed ID: 17032238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.
    Zanvit P; Havlícková M; Tácner J; Novotná O; Jirkovská M; Cechová D; Julák J; Sterzl I; Prokesová L
    Immunol Lett; 2008 Jan; 115(2):144-52. PubMed ID: 18160106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.
    Liu H; Patil HP; de Vries-Idema J; Wilschut J; Huckriede A
    PLoS One; 2013; 8(7):e69649. PubMed ID: 23936066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of immune responses to influenza vaccine (H3N2) by ginsenoside Re.
    Song X; Chen J; Sakwiwatkul K; Li R; Hu S
    Int Immunopharmacol; 2010 Mar; 10(3):351-6. PubMed ID: 20034596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection.
    Mann JF; Shakir E; Carter KC; Mullen AB; Alexander J; Ferro VA
    Vaccine; 2009 Jun; 27(27):3643-9. PubMed ID: 19464545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal immunization with influenza virus and Korean mistletoe lectin C (KML-C) induces heterosubtypic immunity in mice.
    Song SK; Moldoveanu Z; Nguyen HH; Kim EH; Choi KY; Kim JB; Mestecky J
    Vaccine; 2007 Aug; 25(34):6359-66. PubMed ID: 17640781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
    Asanuma H; Fujihashi K; Miyakoshi T; Yoshikawa T; Fujita-Yamaguchi Y; Kojima N; Nakata M; Suzuki Y; Tamura S; Kurata T; Sata T
    Vaccine; 2007 Sep; 25(39-40):6975-80. PubMed ID: 17716790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice.
    Hauge S; Madhun AS; Cox RJ; Brokstad KA; Haaheim LR
    Scand J Immunol; 2007 Jan; 65(1):14-21. PubMed ID: 17212762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response.
    Minne A; Louahed J; Mehauden S; Baras B; Renauld JC; Vanbever R
    Immunology; 2007 Nov; 122(3):316-25. PubMed ID: 17521369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization.
    Audouy SA; van Roosmalen ML; Neef J; Kanninga R; Post E; van Deemter M; Metselaar H; van Selm S; Robillard GT; Leenhouts KJ; Hermans PW
    Vaccine; 2006 Jun; 24(26):5434-41. PubMed ID: 16757068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.